According to the researchers, there are limited effective treatment options for relapsed SCLC after first-line immunotherapy ...

Ask most financial planners how they entered the profession and you’ll often hear a surprisingly unplanned story.

Johnson & Johnson's (J&J's) Rybrevant (amivantamab-vmjw) plus chemotherapy has been linked to the longest median overall survival (OS) seen in a Phase III trial in patients with advanced non-small ...

Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival (PFS) demonstrated by its OX40 agonist ...

Local consolidative therapy (LCT) after induction treatment with nivolumab (Opdivo) plus ipilimumab (Yervoy) failed to ...

Elevra’s Chief Executive Officer and Managing Director, Mr Lucas Dow, said: “The NAL Expansion PFS confirms a compelling value proposition for Elevra, with a high-return brownfield expansion that ...

(Alliance News) - Guardian Metal Resources PLC on Monday announced drilling results that it said support the potential for resource growth at its Pilot Mountain project.

Dakota Gold Corp. (NYSE American: DC) ("Dakota Gold" or the "Company") is pleased to provide results from the Pre-Feasibility Study ("PFS") metallurgical test program for its Richmond Hill Oxide Heap ...

Analysts propose that this positive readout in ES-SCLC could see Imdelltra move into the frontline setting within this indication.

Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a ...

Olema Pharmaceuticals gets a Hold rating again as its current valuation reflects both potential and significant execution risks. Click for an OLMA update.